Princeton Alpha Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Princeton Alpha Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-26,280	Closed	-$111K	–	458
2017 Q1	$111K	Sell	26,280 -3,297	-11%	-$13.7K	0.04%	511
2016 Q4	$122K	Buy	+29,577	New	+$157K	0.03%	646
2016 Q3	–	Sell	-13,912	Closed	-$109K	–	1019
2016 Q2	$109K	Buy	+13,912	New	+$119K	0.02%	725
2015 Q2	–	Sell	-82,412	Closed	-$813K	–	962
2015 Q1	$813K	Buy	82,412 +15,639	+23%	+$195K	0.17%	167
2014 Q4	$818K	Buy	+66,773	New	+$815K	0.23%	109
2014 Q3	–	Sell	-81,113	Closed	-$614K	–	891
2014 Q2	$614K	Buy	+81,113	New	+$324K	0.13%	245

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Princeton Alpha Management's ACHN Position: Q2 2017 in Review

Princeton Alpha Management sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 26,280 shares — an estimated $111K sold.

Princeton Alpha Management first reported a position in ACHN in Q2 2014 and held it in 6 quarters. The position peaked at $818K in Q4 2014. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

Princeton Alpha Management reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Princeton Alpha Management sold 26,280 Achillion Pharmaceuticals shares in Q2 2017, an estimated $111K.
Princeton Alpha Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 6 quarters.
Princeton Alpha Management's Achillion Pharmaceuticals position peaked at $818K in Q4 2014.
129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Princeton Alpha Management's 13F filing for Q2 2017.